retatrutide triple agonist glp-1 gip glucagon receptor Treatment with retatrutide, an agonist to GLP-1 LY3437943, a novel triple glucagon,
Description
Stress and cortisol: Life stress doesnt magically decrease at 40
These factors, combined with robust clinical evidence demonstrating efficacy in glycemic control and weight management, ensure North America retains the largest market share for GLP-1 receptor agonists globally
Tan HC et al
DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P
More serious side effects include pancreatitis, changes in vision, low blood sugar (hypoglycemia), allergic reactions, acute kidney injury, and severe stomach problems
Research continues, but immediate approval in this indication now appears unlikely
